CORONAVIRUS

Final US hurdle for Merck’s COVID-19 pill: FDA panel review

Nov 30, 2021, 9:31 AM
(Merck via CNN)...
(Merck via CNN)
(Merck via CNN)

WASHINGTON (AP) — An experimental COVID-19 drug that could soon become the first U.S.-authorized pill to treat the coronavirus faces one final hurdle Tuesday: A panel of government experts will scrutinize data on the medication from drugmaker Merck.

The Food and Drug Administration is asking its outside experts whether the agency should authorize the pill, weighing new information that it is less effective than first reported and may cause birth defects. The panel’s recommendations aren’t binding but often guide FDA decisions.

Tuesday’s meeting comes as U.S. infections are rising again and health authorities worldwide scramble to size up the threat posed by the new omicron variant.

If authorized, Merck’s pill would be the first that U.S. patients could take at home to ease symptoms and speed recovery, a major step toward reducing hospital case loads and deaths. The drug, molnupiravir, is already authorized for emergency use in the U.K.

Given the ongoing threat of the pandemic the FDA is widely expected to approve emergency use of Merck’s pill. But new data released last week paint a less compelling picture of the drug than when the Merck first publicized its early results in October.

On Friday, Merck said final study results showed molnupiravir reduced hospitalization and death by 30% among adults infected with the coronavirus, significantly lower than the 50% reduction it first announced based on incomplete results.

FDA regulators said they were still reviewing Merck’s update and would present a new assessment of the drug’s benefits to the outside panel. Molnupiravir’s effectiveness is a key question as panel members weigh whether to recommend the drug and for whom.

One key question is whether the drug should be restricted from use in pregnant women or women of child-bearing age.

In its safety review, FDA staffers said animal studies suggested Merck’s drug could cause birth defects when given at high doses. Regulators said they are considering a complete ban on molnupiravir’s use during pregnancy and other safeguards, including recommending contraceptives for some patients taking the pills.

Merck’s drug uses a novel approach to fight COVID-19: it inserts tiny errors into the coronavirus’ genetic code to stop the virus from reproducing. That genetic effect has raised concerns that the drug could cause mutations in human fetuses or even spur more virulent strains of the virus.

Another key question is whether the drug should be offered to patients who have been vaccinated or previously had COVID-19. Merck didn’t study the drug in vaccinated people, but data from a handful of patients with prior infections suggested it had little benefit. Still, it may be impractical for doctors to screen out those patients. The Merck drug works best when given within five days of first COVID-19 symptoms, underscoring the need for speedy treatment.

Merck tested the drug in adults with mild-to-moderate COVID-19 who were considered higher risk due to health problems like obesity, diabetes or heart disease. That’s the same group that currently receives antibody drugs, which help the immune system fight the virus. The FDA has authorized three antibody drugs for COVID-19 but all have to given by IV or injection at hospitals or clinics.

Merck was the first company to submit its COVID-19 pill to the FDA, but a rival drug from Pfizer is close behind and is also under review.

Pfizer’s drug is part of a decades-old family of antiviral pills known as protease inhibitors, a standard treatment for HIV and hepatitis C. They work differently than Merck’s pill and haven’t been linked to the kind of mutation concerns raised with Merck’s drug.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

KSL 5 TV Live

Top Stories

Coronavirus

People line up for nucleic acid testing in Sanya, 'China's Hawaii', on August 6. (VCG/Getty Images)...
Simone McCarthy and CNN's Beijing bureau

Covid lockdown strands 80,000 tourists in ‘China’s Hawaii’

Around 80,000 tourists are stranded in the popular resort city of Sanya on China's tropical Hainan island after authorities announced lockdown measures to stem an outbreak of Covid-19.
2 days ago
TOKYO, JAPAN - JUNE 29: Women in rental kimonos walk through the Asakusa area on June 29, 2022 in T...
Lilit Marcus, CNN

Japan is open to travel. So why aren’t tourists coming back?

Even though Japan partially reopened its borders for tourists, only about 1,500 visitors went to the country during its peak travel season.
9 days ago
President Joe Biden removes his mask as he delivers remarks on the Inflation Reduction Act of 2022 ...
ZEKE MILLER, Associated Press

Biden tests positive for COVID-19, returns to isolation

The White House says President Joe Biden tested positive for COVID-19 again Saturday, slightly more than three days after he was cleared to exit coronavirus isolation.
10 days ago
ATLANTA, GA - UNDATED:  This undated handout photo from the Centers for Disease Control and Prevent...
Jed Boal

U of U researcher joins international team to confirm specific origin of COVID-19

New research released Tuesday confirmed the origin of COVID-19. A University of Utah Health and an international team of researchers found that the earliest cases of COVID-19 in humans emerged at a wholesale fish market in Wuhan, China in December 2019.
14 days ago
U.S. President Joe Biden gives the thumbs up while reacting to questions from the press about how h...
CHRIS MEGERIAN, Associated Press

Doctor: Biden’s COVID symptoms ‘almost completely resolved’

President Joe Biden's COVID-19 symptoms have “almost completely resolved," according to a new note from his doctor released Monday.
15 days ago
Employees check out customers at the 2nd Street second hand store, on Monday, July 19, 2021, in the...
Alaa Elassar and Kacey Cherry, CNN

Indoor mask mandate may be reinstated in LA County amid high COVID-19 transmission level

Los Angeles County is maintaining a high COVID-19 community level, which means a universal indoor masking mandate could be enacted as soon as next week, health officials say.
18 days ago

Sponsored Articles

tips how to quit smoking...

7 Tips How to Quit Smoking | Quitting Smoking Might be One of the Hardest Things You Ever Do but Here’s Where You Can Start

Quitting smoking cigarettes can be incredibly difficult. Here are 7 tips how to quit smoking to help you on your quitting journey.
Photo: Storyblocks...
Blue Stakes of Utah 811

Blue Stakes of Utah 811: 5 Reasons To Call 811 Before You Dig When Working in Your Yard

Call before you dig. Even at home, you could end up with serious injuries or broken utilities just because you didn't call Blue Stakes of Utah 811.
Days of...
Days of '47 Rodeo

TRIVIA: How well do you know your rodeo? Take this quiz before you go to the Days of ’47!

The Utah Days of ’47 Rodeo presented by Zions Bank is a one-of-a-kind Gold Medal Rodeo being held July 20-23, 25 at 7:30 PM. The Days of ’47 Rodeo How well do you know your rodeo trivia? Take the quiz to test your know-all before heading out to the Days of ’47 Rodeo at the […]
cyber security through multi factor authentication setup...
Les Olson IT

How multi factor authentication setup helps companies stay safe

Multi factor authentication (MFA) setup is an important security measure that every company should implement for their workers. It’s also wise to install it for your personal and home accounts.
...
Lighting Design

Check out these stunning lamps with stained glass shades

Lamps with stained glass shades are statement pieces that are more than simply aesthetic. They also meet a functional requirement: to light up a room.
Address Bar of internet browser shows internet access...
AARP Utah

Utah voters 50+ support increased access to Internet

The AARP surveyed Utah voters aged 50 plus about internet access and if they support the expansion of broadband, especially in rural areas currently lacking it.
Final US hurdle for Merck’s COVID-19 pill: FDA panel review